Newsletter Highlights

1. Scientific poster accepted at AACR Ovarian Cancer Conference
2. Strategic partnership signed with Prestige Biopharma for pancreatic cancer
3. Imagion supports Breast Cancer Awareness Month in October
4. Upcoming events and other news 

AACR Ovarian Cancer Poster Accepted

We are pleased to confirm, we have a scientific poster related to our ovarian cancer detection program that will be presented at the AACR Special Conference on Ovarian Cancer, being held from October 5-7, 2023 in Boston, Massachusetts.

Poster Title: In Vivo Ovarian Cancer Detection Using Folate Receptor-α Targeted Iron Oxide Nanoparticles

Date/Time: Friday, Oct 6, 7:00 p.m.- 9:30 p.m. EST

Poster Session: #B045

Partnership with Prestige Biopharma

Prestige Biopharma Group and Imagion Biosystems have established a strategic partnership to jointly pursue the development of the world’s first non-invasive early detection diagnosis and staging platform for pancreatic cancer.

October is Breast Cancer Awareness Month

Imagion is committed to supporting Breast Cancer Awareness Month in recognition of the importance of raising awareness about the disease, promoting early detection through screenings, and demonstrating our solidarity with those affected. By doing so, we aim to contribute to the broader effort to improve research, treatment, and support for individuals impacted by breast cancer.

DON'T FORGET THIS NANONEWS

Presenting at BIO Investor Forum

Imagion's CEO, Isaac Bright, MD will be presenting at the BIO Investor Forum in San Francisco, CA on October 17, 2023, to discuss the company's investment opportunities. EVENT INFO >>

Spotlight Poster at SABCS 

Our latest research based on our MagSense® HER2 program has been selected for a presentation in the Poster Spotlight Discussion session entitled “Shining a new light on breast cancer: Novel molecular and functional imaging approaches to detect and characterize breast cancer" on Wed, December 6 in San Antonio, TX. EVENT INFO >> 

Organizational & MagSense^® HER2 Program Updates

In this announcement, we covered our organizational changes and an update on our MagSense HER2 Program. READ MORE >>

R&D Tax Incentive Refund Received 

In mid-September 2023, Imagion received a AU$3.5 million 2022 R&D tax incentive refund from the Australian Taxation Office. READ MORE >>

Pitt Street Research Report Available 

Pitt Street Research published a 27-page overview report on Imagion Biosystems, Limited. This detailed report includes close examinations of the company’s business and investment potential. GET THE REPORT >>

Join Our Interactive Investor Hub

Engage with us directly by asking questions, watching video summaries, and seeing what other
shareholders have to say about this and past announcements at our Investor Hub: JOIN HERE >>